Tags : Shanghai Fosun

Shanghai Fosun Signs an Exclusive License Agreement with ReNeuron for

Shots: ReNeuron to receive £6.0M ($7.9M) upfront, £6.0M ($7.9M) near-term milestones, £8.0M ($10.5M) regulatory milestones and post-launch profit threshold milestones of 5% on annual profit, leading to total milestones £80.0M ($104.8M) and 12%,14% royalties on net sales of product in China Fosun to get exclusive rights to develop and commercialize ReNeuron’s CTX and hRPC cell […]Read More